Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Rhea-AI Summary

Vigil Neuroscience, Inc. announced the participation of its President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference. The webcast will be available on the company's website, and an archived webcast will be accessible for approximately 90 days after the presentation.

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, at 1:30 p.m. E.T.

To register for the live event, please click here. The webcast will also be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. An archived webcast will be available for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
MacDougall Advisors
mmcgrath@macdougall.bio

FAQ

When is the Guggenheim 6th Annual Biotechnology Conference?

The Guggenheim 6th Annual Biotechnology Conference is on Thursday, February 8.

Who will participate in the fireside chat at the conference?

Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer of Vigil Neuroscience, Inc.

Where can I register for the live event?

To register for the live event, you can click on the provided link.

Where can I access the webcast of the event?

The webcast will be available on the company’s website on the “Events & Presentations” page in the “Investors” section.

How long will the archived webcast be available?

An archived webcast will be available for approximately 90 days following the presentation.